Impact of HAART on survival, weight gain and resting energy expenditure in HIV-1-infected children in India

Annals of Tropical Paediatrics

Volumn 30, Issue 1, 2010, Pages 27-37

  Banerjee, T ^a   Pensi, T ^b   Banerjee, D ^c   Grover, G ^a  

^a UNIVERSITY OF DELHI   (India)

^b DR RAM MANOHAR LOHIA HOSPITAL   (India)

^c INSTITUTE OF HUMAN BEHAVIOUR AND ALLIED SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; BODY MASS; CALORIC INTAKE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD DEATH; CHILD HEALTH; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; ENERGY EXPENDITURE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; INDIA; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUTRITIONAL SUPPORT; PERINATAL INFECTION; PRESCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT FAILURE; WEIGHT CHANGE; WEIGHT GAIN;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD NUTRITIONAL PHYSIOLOGICAL PHENOMENA; CHILD, PRESCHOOL; COHORT STUDIES; ENERGY METABOLISM; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDIA; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LONGITUDINAL STUDIES; MALE; WEIGHT GAIN;

EID: 77749324213     PISSN: 02724936     EISSN: 14653281     Source Type: Journal    
DOI: 10.1179/146532810X12637745451915     Document Type: Article

References (38)

1. Viani RM, Araneta MRG, Deville JG, Spector SA. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis 2004;39:725-31.
2. Becquet R, Mofenson LM. Early antiretroviral therapy of HIV-infected infants in resource-limited countries: possible, feasible, effective and challenging. AIDS 2008;22:1365-8.
3. Sanchez Granados JM, Ramos Amador JT, Fernandez de Miguel S, et al. Impact of highly active antiretroviral therapy on morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003;22:863-7.
4. De Beaudrap P, Rouet F, Fassinou P, et al. CD4 cell response before and after HAART initiation according to viral load and growth indicators in HIV-1-infected children in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2008;49:70-6.
5. Buonora S, Nogueira S, Pone MV, et al. Growth parameters in HIV-vertically-infected adolescents on antiretroviral therapy in Rio de Janeiro, Brazil. Ann Trop Paediatr 2008;28:59-64.
6. Kabue MM, Kekitiinwa A, Maganda A, et al. Growth in HIV-infected children receiving antire-troviral therapy at a pediatric infectious diseases clinic in Uganda. AIDS Patient Care STDS 2008;22:245-51.
7. d'Arminio Monforte A, Musicco M, Galli M, Rezza G. Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS-906 Study Group. Eur J Clin Microbiol Infect Dis 1997;16:135-42.
8. Spector SA. HIV therapy advances. Pediatric antiretroviral choices. AIDS 1994;8 (suppl 3):S15-18.
9. Lindsey JC, Hughes MD, McKinney RE, et al. Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA, CD4 cell counts as predictors of weight growth failure, cognitive decline and survival in HIV-infected children. J Infect Dis 2000;182:1385-93.
10. Chearskul S, Chotpitayasunondh T, Simonds RJ, et al. Survival, disease manifestation and early predictors of disease progression among children with perinatal human immunodeficiency virus infection in Thailand. Pediatrics 2002;110:25-30.
11. Batterham MJ, Garsia R, Greenop P. Prevalence and predictors of HIV-associated weight loss in the era of highly active antiretroviral therapy. Int J STD AIDS 2002;13:744-7.
12. Woods MN, Spiegelman D, Knox TA, et al. Nutrient intake and body weight in a large HIV cohort that includes women and minorities. J Am Diet Assoc 2002;102:203-11.
13. Alfaro MP, Siegel RM, Baker RC, Heubi JE. Resting energy expenditure and body composition in pediatric HIV infection. Pediatr AIDS HIV Infect 1995;6:276-80.
14. Wade A, Ades A. Age-related reference ranges: significance tests for models and confidence intervals for centiles. Stat Med 1994;13:2359-67.
15. US Department of Health and Human Services, HIV/AIDS Treatment Information Service. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection [updated on 3 November 2005]. http://aidsinfo.nih. gov/ContentFiles/PediatricGuidelines.pdf. Access: 20/11/2005.
16. Cole TJ, Green PJ. Smoothing reference centile curves: the LMS method and penalized likelihood. Stat Med 1992;11:1305-19.
17. Food and Nutrition Board. Recommended Daily Allowances, 10th edn. Washington, DC: National Academy Press, 1989; 32-3.
18. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 1949;109:1-9.
19. Thorne C, Newell ML, Asensi-Bostet F, et al. Older children and adolescents surviving with vertically acquired HIV infection. European Collaborative Study. J Acquir Immune Defic Syndr 2002;29:396-10.
20. de Martino M, Tovo PA, Galli L, et al. Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 children. AIDS 2001;15:1527-34.
21. Taha TE, Graham SM, Kumwenda NI, et al. Morbidity among human immunodeficiency virus-1-infected and uninfected African children. Pediatrics 2000;106:e77.
22. Matida LH, Marcopito LF, Menezes Succi RC, et al. Improving survival among Brazilian children with perinatally-acquired AIDS. Braz J Infect Dis 2004;8:419-23.
23. Newell ML, Cooradin H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004;364:1236-43.
24. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 2000;284:190-7.
25. Teglas J, Mayaux M, Blanche S, et al. Antiretroviral therapy and mortality among children with perinatal HIV infection. JAMA 2000;284:2871-2.
26. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345:1522-8.
27. Frederick T, Mascola L, Peters V, Bertolli J, Weedon J. Trends in HAART use and immune status among HIV-infected infants and children in the Pediatric Spectrum of Disease project, United States, 1994-2000 [abstract TuPeC4735]. In: Programs and Abstracts of the XIV International Conference on AIDS. Barcelona: 7-12 July 2002.
28. European Collaborative Study. Fluctuations in symptoms in HIV-infected children: the first 10 years of life. Pediatrics 2001;108:116-22.
29. Luzuriaga K, McManus M, Mofenson LM, Britto P, Graham BS, Sullivan JL. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 2004;350:2471-80.
30. Soh C-H, Oleske JM, Spector SA, et al. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet 2003;362:2045-51.
31. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007;298:1888-99.
32. van de Perre P. Management of HIV-infected children in Europe. Acta Paediatr 2003;92:139-40.
33. Thuret I. When to initiate antiretroviral therapy in HIV-infected children? Arch Pediatr 2004;11:1521-4.
34. Yogev R. Balancing the upside and downside of antiretroviral therapy in children. JAMA 2005;293:2272-4.
35. European Collaborative Study. Are there gender and race differences in cellular immunity patterns over age in infected and uninfected children born to HIV-infected women? J Acquir Immune Defic Syndr 2003;33:635-41.
36. Shevitz AH. Management trends: resting energy expenditure in the HAART era. AIDS Reader 2000;10:539-44, 557-8.
37. Johann-Liang R, O'Neill L, Cervia J, et al. Energy balance, viral burden, insulin-like growth factor-1, interleukin-6 and growth impairment in children infected with human immunodeficiency virus. AIDS 2000;14:683-90.
38. Arpadi SM, Ceiff PA, Kotler DP, et al. Growth velocity, fat-free mass and energy intake are inversely related to viral load in HIV-infected children. J Nutr 2000;130:2498-502.